Aripiprazole Patent Expiration
Aripiprazole is used for acute treatment of manic and mixed episodes associated with bipolar I disorder, adjunctive treatment of major depressive disorder (MDD), and treatment of schizophrenia. It was first introduced by Otsuka Pharmaceutical Co Ltd
Aripiprazole Patents
Given below is the list of patents protecting Aripiprazole, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Opipza | US11701352 | Process for preparing aripiprazole oral soluble film | Dec 15, 2041 | Xiamen Lp Pharm Co |
| Opipza | US11331315 | Aripiprazole oral soluble film | Nov 03, 2040 | Xiamen Lp Pharm Co |
| Abilify Mycite Kit | US10097388 | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping | Sep 19, 2034 | Otsuka |
| Abilify Mycite Kit | US9270503 | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping | Sep 19, 2034 | Otsuka |
| Abilify Mycite Kit | US9787511 | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping | Sep 19, 2034 | Otsuka |
| Abilify Maintena Kit | US11648347 | Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient | Apr 06, 2034 | Otsuka Pharm Co Ltd |
| Abilify Maintena Kit | US10525057 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | Mar 08, 2034 | Otsuka Pharm Co Ltd |
| Abilify Mycite Kit | US9268909 | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device | Oct 15, 2033 | Otsuka |
| Abilify Mycite Kit | US9577864 | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance | Oct 03, 2033 | Otsuka |
| Abilify Maintena Kit | US10980803 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | Sep 24, 2033 | Otsuka Pharm Co Ltd |
| Abilify Maintena Kit | US11154553 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | Sep 24, 2033 | Otsuka Pharm Co Ltd |
| Abilify Maintena Kit | US11344547 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | Sep 24, 2033 | Otsuka Pharm Co Ltd |
| Abilify Maintena Kit | US11400087 | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function | Sep 24, 2033 | Otsuka Pharm Co Ltd |
| Mezofy | US9694008 | Fast-dissolving oral film preparation comprising aripiprazole | Aug 07, 2033 | Cmg Pharm Co Ltd |
| Abilify Asimtufii | US10517951 | Injectable preparation | Apr 23, 2033 | Otsuka |
| Abilify Asimtufii | US11097007 | Injectable preparation | Apr 23, 2033 | Otsuka |
| Abilify Asimtufii | US11638757 | Injectable preparation | Apr 23, 2033 | Otsuka |
| Abilify Asimtufii | US12016927 | Injectable preparation | Apr 23, 2033 | Otsuka |
| Abilify Mycite Kit | US10517507 | Communication system with enhanced partial power source and method of manufacturing same | Jun 13, 2032 | Otsuka |
| Abilify Mycite Kit | US9320455 | Highly reliable ingestible event markers and methods for using the same | Dec 15, 2031 | Otsuka |
| Abilify Mycite Kit | US11229378 | Communication system with enhanced partial power source and method of manufacturing same | Jul 11, 2031 | Otsuka |
| Abilify Mycite Kit | US8547248 | Implantable zero-wire communications system | Dec 18, 2030 | Otsuka |
| Abilify Mycite Kit | US8258962 | Multi-mode communication ingestible event markers and systems, and methods of using the same | Nov 25, 2030 | Otsuka |
| Abilify Mycite Kit | US8961412 | In-body device with virtual dipole signal amplification | Nov 17, 2030 | Otsuka |
| Abilify Mycite Kit | US9941931 | System for supply chain management | Nov 04, 2030 | Otsuka |
| Abilify Mycite Kit | US11464423 | In-body power source having high surface area electrode | Sep 15, 2030 | Otsuka |
| Abilify Mycite Kit | US8114021 | Body-associated receiver and method | Jun 21, 2030 | Otsuka |
| Abilify Mycite Kit | US8545402 | Highly reliable ingestible event markers and methods for using the same | Apr 27, 2030 | Otsuka |
| Abilify Mycite Kit | US8847766 | Pharma-informatics system | Mar 29, 2030 | Otsuka |
| Abilify Mycite Kit | US9149577 | Body-associated receiver and method | Dec 15, 2029 | Otsuka |
| Abilify Mycite Kit | US8718193 | Active signal processing personal health signal receivers | Dec 05, 2029 | Otsuka |
| Abilify Mycite Kit | US9433371 | In-body device with virtual dipole signal amplification | Sep 15, 2029 | Otsuka |
| Abilify Mycite Kit | US8945005 | Controlled activation ingestible identifier | Aug 19, 2029 | Otsuka |
| Abilify Mycite Kit | US10441194 | Ingestible event marker systems | Jul 26, 2029 | Otsuka |
| Abilify Mycite Kit | US8956288 | In-body power source having high surface area electrode | Jul 06, 2029 | Otsuka |
| Abilify Mycite Kit | US8674825 | Pharma-informatics system | Apr 09, 2029 | Otsuka |
| Abilify Mycite Kit | US9060708 | Multi-mode communication ingestible event markers and systems, and methods of using the same | Mar 05, 2029 | Otsuka |
| Abilify Mycite Kit | US9258035 | Multi-mode communication ingestible event markers and systems, and methods of using the same | Mar 05, 2029 | Otsuka |
| Abilify Mycite Kit | US9119554 | Pharma-informatics system | Dec 16, 2028 | Otsuka |
| Abilify Mycite Kit | US9444503 | Active signal processing personal health signal receivers | Nov 19, 2027 | Otsuka |
| Abilify | US8759350 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | Mar 02, 2027 | Otsuka |
| Abilify | US8759350 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | Mar 02, 2027 | Otsuka |
| Abilify Mycite Kit | US8759350 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | Mar 02, 2027 | Otsuka |
| Abilify Mycite Kit | US7978064 | Communication system with partial power source | Sep 14, 2026 | Otsuka |
| Abilify | US9125939 | Carbostyril derivatives and mood stabilizers for treating mood disorders | Jul 28, 2026 | Otsuka |
| Abilify Mycite Kit | US9125939 | Carbostyril derivatives and mood stabilizers for treating mood disorders | Jul 28, 2026 | Otsuka |
| Abilify Mycite Kit | US11476952 | Pharma-informatics system | Apr 28, 2026 | Otsuka |
| Abilify Asimtufii | US8399469 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun 29, 2025
(Expired) | Otsuka |
| Abilify Maintena Kit | US8399469 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun 29, 2025
(Expired) | Otsuka Pharm Co Ltd |
| Abilify Asimtufii | US8338427 | Methods for administering aripiprazole |
Mar 15, 2025
(Expired) | Otsuka |
| Abilify Maintena Kit | US8338427 | Methods for administering aripiprazole |
Mar 15, 2025
(Expired) | Otsuka Pharm Co Ltd |
| Abilify |
US7115587 (Pediatric) | Aripiprazole complex formulation and method |
Jan 21, 2025
(Expired) | Otsuka |
| Abilify |
US7550445 (Pediatric) | Aripiprazole complex formulation and method |
Jan 21, 2025
(Expired) | Otsuka |
| Abilify |
US8017615 (Pediatric) | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Dec 16, 2024
(Expired) | Otsuka |
| Abilify Maintena Kit | US7807680 | Controlled release sterile injectable aripiprazole formulation and method |
Oct 19, 2024
(Expired) | Otsuka Pharm Co Ltd |
| Abilify Maintena Kit | US8030313 | Controlled release sterile injectable aripiprazole formulation and method |
Oct 19, 2024
(Expired) | Otsuka Pharm Co Ltd |
| Abilify Maintena Kit | US8722679 | Controlled release sterile injectable aripiprazole formulation and method |
Oct 19, 2024
(Expired) | Otsuka Pharm Co Ltd |
| Abilify | US7115587 | Aripiprazole complex formulation and method |
Jul 21, 2024
(Expired) | Otsuka |
| Abilify | US7550445 | Aripiprazole complex formulation and method |
Jul 21, 2024
(Expired) | Otsuka |
| Abilify | US8017615 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun 16, 2024
(Expired) | Otsuka |
| Abilify Mycite Kit | US8017615 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun 16, 2024
(Expired) | Otsuka |
| Abilify | US9387182 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec 25, 2023
(Expired) | Otsuka |
| Abilify | US9387182 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec 25, 2023
(Expired) | Otsuka |
| Abilify Mycite Kit | US9387182 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec 25, 2023
(Expired) | Otsuka |
| Abilify Asimtufii | US8338428 | Methods for administering aripiprazole |
Aug 06, 2023
(Expired) | Otsuka |
| Abilify Asimtufii | US8759351 | Methods for administering aripiprazole |
Aug 06, 2023
(Expired) | Otsuka |
| Abilify Maintena Kit | US8338428 | Methods for administering aripiprazole |
Aug 06, 2023
(Expired) | Otsuka Pharm Co Ltd |
| Abilify Maintena Kit | US8759351 | Methods for administering aripiprazole |
Aug 06, 2023
(Expired) | Otsuka Pharm Co Ltd |
| Abilify |
US8580796 (Pediatric) | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar 25, 2023
(Expired) | Otsuka |
| Abilify |
US8642760 (Pediatric) | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar 25, 2023
(Expired) | Otsuka |
| Abilify |
US6977257 (Pediatric) | Aripiprazole oral solution |
Oct 24, 2022
(Expired) | Otsuka |
| Abilify | US8580796 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep 25, 2022
(Expired) | Otsuka |
| Abilify | US8642760 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep 25, 2022
(Expired) | Otsuka |
| Abilify | US9359302 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep 25, 2022
(Expired) | Otsuka |
| Abilify Maintena Kit | US8993761 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep 25, 2022
(Expired) | Otsuka Pharm Co Ltd |
| Abilify Mycite Kit | US8580796 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep 25, 2022
(Expired) | Otsuka |
| Abilify Mycite Kit | US8642760 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep 25, 2022
(Expired) | Otsuka |
| Abilify Mycite Kit | US9359302 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep 25, 2022
(Expired) | Otsuka |
| Abilify |
US8642600 (Pediatric) | Method of treating autism |
Jul 28, 2022
(Expired) | Otsuka |
| Abilify |
US8642600 (Pediatric) | Method of treating autism |
Jul 28, 2022
(Expired) | Otsuka |
| Abilify | US6977257 | Aripiprazole oral solution |
Apr 24, 2022
(Expired) | Otsuka |
| Abilify | US7053092 | 5-HT1a receptor subtype agonist |
Jan 28, 2022
(Expired) | Otsuka |
| Abilify | US7053092 | 5-HT1a receptor subtype agonist |
Jan 28, 2022
(Expired) | Otsuka |
| Abilify | US8642600 | Method of treating autism |
Jan 28, 2022
(Expired) | Otsuka |
| Abilify | US8642600 | Method of treating autism |
Jan 28, 2022
(Expired) | Otsuka |
| Abilify | US9089567 | Method of treating cognitive impairments and schizophrenias |
Jan 28, 2022
(Expired) | Otsuka |
| Abilify Maintena Kit | US9089567 | Method of treating cognitive impairments and schizophrenias |
Jan 28, 2022
(Expired) | Otsuka Pharm Co Ltd |
| Abilify Mycite Kit | US7053092 | 5-HT1a receptor subtype agonist |
Jan 28, 2022
(Expired) | Otsuka |
| Abilify Mycite Kit | US9089567 | Method of treating cognitive impairments and schizophrenias |
Jan 28, 2022
(Expired) | Otsuka |
| Abilify |
US8518421 (Pediatric) | Flashmelt oral dosage formulation |
Jul 24, 2021
(Expired) | Otsuka |
| Abilify | US8518421 | Flashmelt oral dosage formulation |
Jan 24, 2021
(Expired) | Otsuka |
| Abilify | US9358207 | Flashmelt oral dosage formulation |
Apr 12, 2020
(Expired) | Otsuka |
| Abilify |
US5006528 (Pediatric) | Carbostyril derivatives |
Apr 20, 2015
(Expired) | Otsuka |
| Abilify |
US5006528 (Pediatric) | Carbostyril derivatives |
Apr 20, 2015
(Expired) | Otsuka |
| Abilify Maintena Kit | US5006528 | Carbostyril derivatives |
Apr 20, 2015
(Expired) | Otsuka Pharm Co Ltd |
| Abilify Maintena Kit |
US5006528 (Pediatric) | Carbostyril derivatives |
Apr 20, 2015
(Expired) | Otsuka Pharm Co Ltd |
| Abilify | US5006528 | Carbostyril derivatives |
Oct 20, 2014
(Expired) | Otsuka |
| Abilify | US5006528 | Carbostyril derivatives |
Oct 20, 2014
(Expired) | Otsuka |
| Abilify Maintena Kit | US5006528 | Carbostyril derivatives |
Oct 20, 2014
(Expired) | Otsuka Pharm Co Ltd |
Aripiprazole's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on Aripiprazole:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry. Aripiprazole has 2 clinical trials that have been verified in 2024. Out of these 2, 1 trial is in PHASE4.